Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.

Kosmider O, Chapuis N, Kaltenbach S, Coriat R, Boudou Rouquette P, Willems L, Chesnais V, Radford-Weiss I, Bardet V, Mayeux P, Tamburini J, Fontenay M, Bouscary D.

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):347-50. doi: 10.1016/j.clml.2012.11.007. No abstract available.

PMID:
23246161
2.

Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.

Antar A, Kharfan-Dabaja MA, Mahfouz R, Bazarbachi A.

Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. doi: 10.1016/j.clml.2014.12.005. Epub 2014 Dec 12.

PMID:
25550214
3.

High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.

De Freitas T, Marktel S, Piemontese S, Carrabba MG, Tresoldi C, Messina C, Lupo Stanghellini MT, Assanelli A, Corti C, Bernardi M, Peccatori J, Vago L, Ciceri F.

Eur J Haematol. 2016 Jun;96(6):629-36. doi: 10.1111/ejh.12647. Epub 2015 Sep 21.

PMID:
26260140
4.

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.

Sammons SL, Pratz KW, Smith BD, Karp JE, Emadi A.

Am J Hematol. 2014 Sep;89(9):936-8. doi: 10.1002/ajh.23782. Epub 2014 Jun 23. No abstract available.

5.

Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.

Tarlock K, Chang B, Cooper T, Gross T, Gupta S, Neudorf S, Adlard K, Ho PA, McGoldrick S, Watt T, Templeman T, Sisler I, Garee A, Thomson B, Woolfrey A, Estey E, Meshinchi S, Pollard JA.

Pediatr Blood Cancer. 2015 Jun;62(6):1048-54. doi: 10.1002/pbc.25437. Epub 2015 Feb 8.

PMID:
25662999
6.

Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.

Gill H, Man CH, Ip AH, Choi WW, Chow HC, Kwong YL, Leung AY.

Haematologica. 2015 Jul;100(7):e250-3. doi: 10.3324/haematol.2014.123034. Epub 2015 Mar 27. No abstract available.

7.

[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].

Zu YL, Zhang YL, Zhou J, Han LJ, Zhao HF, Gui RR, Hou YJ, Song YP.

Zhonghua Nei Ke Za Zhi. 2016 Aug 1;55(8):634-6. doi: 10.3760/cma.j.issn.0578-1426.2016.08.014. Chinese.

PMID:
27480560
8.

[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].

Jiang ZH, Feng FE, Lin XQ, Lu J.

Zhonghua Xue Ye Xue Za Zhi. 2013 Aug;34(8):736. doi: 10.3760/cma.j.issn.0253-2727.2013.08.023. Chinese. No abstract available.

PMID:
23978034
9.

Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.

von Bubnoff N, Rummelt C, Menzel H, Sigl M, Peschel C, Duyster J.

Leukemia. 2010 Aug;24(8):1523-5. doi: 10.1038/leu.2010.122. Epub 2010 Jun 3. No abstract available.

PMID:
20520641
10.

Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.

Liegel J, Courville E, Sachs Z, Ustun C.

Haematologica. 2014 Nov;99(11):e222-4. doi: 10.3324/haematol.2014.109975. Epub 2014 Jul 11. No abstract available.

11.

A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.

Man CH, Lam SS, Sun MK, Chow HC, Gill H, Kwong YL, Leung AY.

Blood. 2014 Apr 17;123(16):2530-9. doi: 10.1182/blood-2013-07-512194. Epub 2014 Mar 7.

12.

Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.

Fathi AT, Lin WM, Durazzo T, Piris A, Sadrzadeh H, Bernardo L, Borger DR, McAfee SL, Kroshinsky D, Chen YB.

J Clin Oncol. 2016 Mar 10;34(8):e70-2. doi: 10.1200/JCO.2013.50.7582. Epub 2014 Jul 14. No abstract available.

PMID:
25024084
13.

[Successful treatment with sorafenib for primary refractory acute monoblastic leukemia with FLT3-ITD].

Takahashi N, Kawakami T, Sato H, Onoda T, Kanno M, Mitsui T, Hayasaka K.

Rinsho Ketsueki. 2012 Nov;53(11):1932-6. Japanese.

PMID:
23257676
14.

Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia.

Tavil B, Isgandarova F, Bayhan T, Unal S, Kuskonmaz B, Gumruk F, Cetin M.

J Pediatr Hematol Oncol. 2016 Apr;38(3):240-2. doi: 10.1097/MPH.0000000000000521.

PMID:
26907662
15.

Perforating folliculitis-like reaction related to sorafenib.

Eberst E, Rigau V, Pageaux GP, Guillot B, Kluger N.

Cutis. 2014 Jan;93(1):E8-10. No abstract available.

PMID:
24505595
16.

[Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].

Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Okusaka T.

Nihon Shokakibyo Gakkai Zasshi. 2012 Aug;109(8):1346-54. Review. Japanese. No abstract available.

PMID:
22863957
17.

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia.

Cummins KD, Jane SM, Ninkovic S, Bazargan A, Filshie R, Sutrave G, Hertzberg M, Scott A, Lane S, Yannakou CK, Ritchie D, D'Rozario J, Black J, Bavishi K, Wei A.

Blood Cancer J. 2014 Aug 8;4:e237. doi: 10.1038/bcj.2014.59. No abstract available. Erratum in: Blood Cancer J. 2014;4:e246. Nikovic, S [corrected to Ninkovic, S].

18.

Bowel Perforation After Treatment with Sorafenib: A Case Report and Review of Literature.

Hamdeh S, Upadhyay S, Khanal N, Lanspa S.

J Gastrointest Cancer. 2016 Dec;47(4):420-422. No abstract available.

PMID:
26223483
19.

Sorafenib (Nexavar) for thyroid cancer.

[No authors listed]

Med Lett Drugs Ther. 2014 May 26;56(1443):43-4. Review. No abstract available.

PMID:
24869715
20.

Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.

Kashima T, Ohno Y, Tachibana M.

Int J Urol. 2012 Nov;19(11):1041-2. doi: 10.1111/j.1442-2042.2012.03099.x. Epub 2012 Jul 13. No abstract available.

Supplemental Content

Support Center